3-chloro-octahydro-2(1H)-quinolinone | 87624-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉类
• 英文名称: 3-chloro-octahydro-2(1H)-quinolinone
• 英文别名: 3-chloro-cis-octahydro-1H-quinolin-2-one；3-chloro-3,4,4a,5,6,7,8,8a-octahydro-1H-quinolin-2-one
• CAS: 87624-03-1
• 化学式: C₉H₁₄ClNO
• 分子量: 187.669
• InChiKey: LWHALVREUDNLSQ-UHFFFAOYSA-N

物化性质

• 沸点：
  362.4±25.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chloro-octahydro-2(1H)-quinolinone 在 barium dihydroxide 、 硫酸 作用下， 以 水 为溶剂， 反应 5.0h， 生成 八氢-1H-吲哚-2-羧酸
  参考文献：
  名称：

  [EN] PREPARATION OF TRANDOLAPRIL
  [FR] PREPARATION DE TRANDOLAPRIL

  摘要：

  公开号：

  WO2006014916A3
• 作为产物：
  描述：

  3,3-dichloro-octahydro-2(1H)-quinolinone 在 aluminum nickel 三乙胺 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 生成 3-chloro-octahydro-2(1H)-quinolinone
  参考文献：
  名称：

  Derivatives of bicyclic aminoacids agents containing these compounds and

  摘要：

  本发明公开了具有以下式I的顺式、外式和反式化合物： 其中n表示0、1或2，R.sub.1表示氢、(C.sub.1 -C.sub.6)-烷基，该烷基可以选择性地被氨基、(C.sub.1 -C.sub.4)-酰基或苯甲酰氨基取代，(C.sub.2 -C.sub.6)-烯基，(C.sub.5 -C.sub.9)-环烷基，(C.sub.5 -C.sub.9)-环烯基，(C.sub.5 -C.sub.7)-环烷基-(C.sub.1 -C.sub.4)-烷基，芳基或部分氢化芳基代表的基团，该基团在每种情况下可以被(C.sub.1 -C.sub.2)-烷基、(C.sub.1 -C.sub.2)-烷氧基或卤素取代，芳基-(C.sub.1 -C.sub.4)-烷基，/该基团可以如前述在芳基中定义地被取代/，单环或双环硫或氮和/或氮杂环基团，或天然氨基酸的侧链，R.sub.2表示氢、(C.sub.1 -C.sub.6)-烷基，(C.sub.2 -C.sub.6)-烯基或芳基-(C.sub.1 -C.sub.4)-烷基，Y表示氢或羟基，Z表示氢或Y和Z一起表示氧，X表示(C.sub.1 -C.sub.6)-烷基，(C.sub.2 -C.sub.6)-烯基，(C.sub.6 -C.sub.9)-环烷基或芳基，该芳基可以是单取代、双取代或三取代的(C.sub.1 -C.sub.4)-烷基、(C.sub.1 -C.sub.4)-烷氧基、羟基、卤素、硝基、氨基、(C.sub.1 -C.sub.4)-烷基氨基、二-(C.sub.1 -C.sub.4)-烷基氨基或甲亚氧基，或吲哚-3-基，或其生理上可接受的盐，其制备方法，含有它们的制剂，它们作为药物的用途和其制备的中间体。

  公开号：

  US04933361A1

文献信息

• Derivatives of bicyclic aminoacids agents containing these compounds and
  申请人：Hoechst Aktiengesellschaft

  公开号：US04933361A1

  公开（公告）日：1990-06-12

  Disclosed are cis, exo- and trans-compounds of the formula I ##STR1## in which n denotes 0, 1 or 2, R.sub.1 denotes hydrogen, (C.sub.1 -C.sub.6)-alkyl which can optionally be substituted by amino, (C.sub.1 -C.sub.4)-acyl- or bezoylamino, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.5 -C.sub.9)-cycloalkyl, (C.sub.5 -C.sub.9)-cycloalkenyl, (C.sub.5 -C.sub.7)-cycloalkyl-(C.sub.1 -C.sub.4)-alkyl, aryl or partially hydrogenated aryl, which can, in each case, be substituted by (C.sub.1 -C.sub.2)-alkyl, (C.sub.1 -C.sub.2)-alkoxy or halogen, aryl-(C.sub.1 -C.sub.4)-alkyl, /which can be substituted as defined previously in the aryl radical/, a monocyclic or bicyclic sulfur or nitrogen and/or nitrogen heterocyclic radical, or a side chain of naturally occurring aminoacid, R.sub.2 denotes hydrogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.2 -C.sub.6)-alkenyl or aryl-(C.sub.1 -C.sub.4)-alkyl, Y denotes hydrogen or hydroxyl, Z denotes hydrogen or Y and Z together denote oxygen, X denotes (C.sub.1 -C.sub.6)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.6 -C.sub.9)-cycloalkyl or aryl which can be mono-, di- or tri- substituted by (C.sub.1 -C.sub.4)-alkyl, (C.sub.1 -C.sub.4)-alkoxy, hydroxyl, halogen, nitro, amino, (C.sub.1 -C.sub.4)-alkylamino, di-(C.sub.1 -C.sub.4 -alkylamino or methylenedioxy, or indol-3-yl, or physiologically acceptable salts thereof, a process of the preparation thereof, agents containing them, their use as a medicine and intermediates for the preparation thereof.

  本发明公开了具有以下式I的顺式、外式和反式化合物： 其中n表示0、1或2，R.sub.1表示氢、(C.sub.1 -C.sub.6)-烷基，该烷基可以选择性地被氨基、(C.sub.1 -C.sub.4)-酰基或苯甲酰氨基取代，(C.sub.2 -C.sub.6)-烯基，(C.sub.5 -C.sub.9)-环烷基，(C.sub.5 -C.sub.9)-环烯基，(C.sub.5 -C.sub.7)-环烷基-(C.sub.1 -C.sub.4)-烷基，芳基或部分氢化芳基代表的基团，该基团在每种情况下可以被(C.sub.1 -C.sub.2)-烷基、(C.sub.1 -C.sub.2)-烷氧基或卤素取代，芳基-(C.sub.1 -C.sub.4)-烷基，/该基团可以如前述在芳基中定义地被取代/，单环或双环硫或氮和/或氮杂环基团，或天然氨基酸的侧链，R.sub.2表示氢、(C.sub.1 -C.sub.6)-烷基，(C.sub.2 -C.sub.6)-烯基或芳基-(C.sub.1 -C.sub.4)-烷基，Y表示氢或羟基，Z表示氢或Y和Z一起表示氧，X表示(C.sub.1 -C.sub.6)-烷基，(C.sub.2 -C.sub.6)-烯基，(C.sub.6 -C.sub.9)-环烷基或芳基，该芳基可以是单取代、双取代或三取代的(C.sub.1 -C.sub.4)-烷基、(C.sub.1 -C.sub.4)-烷氧基、羟基、卤素、硝基、氨基、(C.sub.1 -C.sub.4)-烷基氨基、二-(C.sub.1 -C.sub.4)-烷基氨基或甲亚氧基，或吲哚-3-基，或其生理上可接受的盐，其制备方法，含有它们的制剂，它们作为药物的用途和其制备的中间体。
• Process for the preparation of intermediates of perindopril
  申请人：Joshi Shriram Narendra

  公开号：US20070032661A1

  公开（公告）日：2007-02-08

  A process for the preparation of (2S, 3aS, 7aS)perhydroindole-2-carboxylic acid is provided comprising (a) esterifying a cis-perhydroindole-2-carboxylic acid with a first alcohol of the formula ROH and a suitable free acid to provide the acid salt (AS) of Formula V: (b) reacting the acid salt of Formula V with a first base to provide a compound of Formula VI: (c) treating the product of step (b) with an L-tartaric containing acid in a second alcohol of the formula ROH to precipitate a compound of Formula VII: (d) reacting the compound of Formula VII with a second base to provide a compound of Formula II (e) hydrolyzing the compound of Formula II to provide the (2S, 3aS, 7aS)perhydroindole-2-carboxylic acid.

  提供一种制备(2S, 3aS, 7aS)环己烷基吲哚-2-羧酸的方法，包括(a)用式为ROH的第一醇和适当的游离酸酯化顺式环己基吲哚-2-羧酸，以得到化合物V的酸盐(AS)：(b)用第一碱处理化合物V的酸盐，得到化合物VI：(c)用含有L-酒石酸的酸处理步骤(b)的产物，使其在式为ROH的第二醇中沉淀出化合物VII：(d)用第二碱处理化合物VII，得到化合物II：(e)水解化合物II，得到(2S, 3aS, 7aS)环己烷基吲哚-2-羧酸。
• Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
  申请人：Cottrell M. Kevin

  公开号：US20070161789A1

  公开（公告）日：2007-07-12

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及式I的化合物：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，它们通过干扰丙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于外体使用还是用于治疗患有HCV感染的患者的给药，以及制备这些化合物的过程。本发明还涉及通过给予本发明的化合物组成物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的过程。
• Inhibitors of serine proteases, particular HCV NS3-NS4A protease
  申请人：Pitlik Janos

  公开号：US20070292933A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性的化合物，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Pitlik Janos

  公开号：US20100173851A1

  公开（公告）日：2010-07-08

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的方法。